• Je něco špatně v tomto záznamu ?

Impact of analgesic regimen on patient outcome following subarachnoid hemorrhage: positive adjuvant effects of metamizole

P. Solar, M. Joukal, C. Silar, R. Jancalek

. 2024 ; 38 (6) : 1304-1311. [pub] 20221205

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003359

INTRODUCTION: Various analgesics are used to control intense headaches in patients following subarachnoid hemorrhage. In addition to pain control, it has been shown that some analgesics can affect various pathophysiological cascades. Therefore, we devised a study to assess whether the use of metamizole has a significant impact on the development of ischemic complications, hydrocephalus, and the overall outcome in patients following aneurysmal subarachnoid hemorrhage in the context of the other non-opioids and opioids effects. METHODS: In our retrospective, single-center cohort study, we enrolled 192 patients diagnosed with subarachnoid hemorrhage. We recorded their initial clinical status, comorbidities, and the daily dosage of analgesics over 14 days of hospitalization after the onset of subarachnoid hemorrhage. Using univariate and subsequent multivariate logistic regression analysis, we assessed the influence of various factors, including analgesics, on the development of delayed cerebral ischemia and hydrocephalus, as well as on 2-week and 6-month outcomes. RESULTS: Although the administration of non-opioids, in general, had no effect on the development of delayed cerebral ischemia or hydrocephalus, the use of metamizole as the main analgesic was associated with a significantly lower chance of poor outcome at both 2-weeks and 6-months, as well as the development of delayed cerebral ischemia. As opioids were indicated primarily for analgosedation in mechanically ventilated patients with poor clinical status, their usage was associated with a significantly higher chance of poor outcome, delayed cerebral ischemia, and hydrocephalus. CONCLUSION: Our results suggest that the prescription of metamizole may be associated with better outcomes and a lower chance of delayed cerebral ischemia development in patients after subarachnoid hemorrhage. Considering the retrospective nature of our study and the limited worldwide availability of metamizole due to its prohibition in some countries, our results do not demonstrate a clear benefit but rather justify the need for subsequent prospective studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003359
003      
CZ-PrNML
005      
20250206104305.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/02688697.2022.2151563 $2 doi
035    __
$a (PubMed)36469604
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Solar, Peter $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, St. Anne's University Hospital Brno, Masaryk University, Brno, Czech Republic
245    10
$a Impact of analgesic regimen on patient outcome following subarachnoid hemorrhage: positive adjuvant effects of metamizole / $c P. Solar, M. Joukal, C. Silar, R. Jancalek
520    9_
$a INTRODUCTION: Various analgesics are used to control intense headaches in patients following subarachnoid hemorrhage. In addition to pain control, it has been shown that some analgesics can affect various pathophysiological cascades. Therefore, we devised a study to assess whether the use of metamizole has a significant impact on the development of ischemic complications, hydrocephalus, and the overall outcome in patients following aneurysmal subarachnoid hemorrhage in the context of the other non-opioids and opioids effects. METHODS: In our retrospective, single-center cohort study, we enrolled 192 patients diagnosed with subarachnoid hemorrhage. We recorded their initial clinical status, comorbidities, and the daily dosage of analgesics over 14 days of hospitalization after the onset of subarachnoid hemorrhage. Using univariate and subsequent multivariate logistic regression analysis, we assessed the influence of various factors, including analgesics, on the development of delayed cerebral ischemia and hydrocephalus, as well as on 2-week and 6-month outcomes. RESULTS: Although the administration of non-opioids, in general, had no effect on the development of delayed cerebral ischemia or hydrocephalus, the use of metamizole as the main analgesic was associated with a significantly lower chance of poor outcome at both 2-weeks and 6-months, as well as the development of delayed cerebral ischemia. As opioids were indicated primarily for analgosedation in mechanically ventilated patients with poor clinical status, their usage was associated with a significantly higher chance of poor outcome, delayed cerebral ischemia, and hydrocephalus. CONCLUSION: Our results suggest that the prescription of metamizole may be associated with better outcomes and a lower chance of delayed cerebral ischemia development in patients after subarachnoid hemorrhage. Considering the retrospective nature of our study and the limited worldwide availability of metamizole due to its prohibition in some countries, our results do not demonstrate a clear benefit but rather justify the need for subsequent prospective studies.
650    _2
$a lidé $7 D006801
650    12
$a subarachnoidální krvácení $x farmakoterapie $x komplikace $7 D013345
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a metamizol $x terapeutické užití $x aplikace a dávkování $7 D004177
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dospělí $7 D000328
650    12
$a antiflogistika nesteroidní $x terapeutické užití $x aplikace a dávkování $7 D000894
650    _2
$a hydrocefalus $x etiologie $7 D006849
650    _2
$a ischemie mozku $x farmakoterapie $7 D002545
650    _2
$a analgetika $x terapeutické užití $x aplikace a dávkování $7 D000700
655    _2
$a časopisecké články $7 D016428
700    1_
$a Joukal, Marek $u Department of Anatomy, Faculty of Medicine, Cellular and Molecular Neurobiology Research Group, Masaryk University, Brno, Czech Republic
700    1_
$a Silar, Cenek $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, St. Anne's University Hospital Brno, Masaryk University, Brno, Czech Republic
700    1_
$a Jancalek, Radim $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, St. Anne's University Hospital Brno, Masaryk University, Brno, Czech Republic
773    0_
$w MED00000872 $t British journal of neurosurgery $x 1360-046X $g Roč. 38, č. 6 (2024), s. 1304-1311
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36469604 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104301 $b ABA008
999    __
$a ok $b bmc $g 2263248 $s 1239366
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 6 $d 1304-1311 $e 20221205 $i 1360-046X $m British journal of neurosurgery $n Br J Neurosurg $x MED00000872
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...